Share this article

According to GlobalData, Axonics is one of 128 product lines sold in the US neuromodulation devices market; these product lines are sold by 17 different manufacturers. The average selling price for Axonics decreased in hospitals, decreased in health systems, and increased outside of hospital facilities in 2022. The price of the Axonics device can be viewed in GlobalData’s micro pricing report and can be retrieved according to purchase date, facility type, bed size, and geographical region. Buy the report here.

Smarter leaders trust GlobalData

The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches.

In addition, the final selling pricing of medical devices is also impacted by the discounting policy of the manufacturer. Companies such as Axonics Modulation Technologies apply discounts for their devices based on their internal business strategy, inventory control, and monthly or quarterly sales targets. In addition, sale location can also affect the final selling price of a device, both in terms of geographical region and facility type. Prices for the same medical device often vary in hospitals and health systems versus outside of hospital facilities, for example if high volume healthcare institutions can negotiate discounts or rebates based on large purchase sizes.

Axonics Modulation Technologies overview

Axonics Inc (Axonics) is a medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. The company offers rechargeable and recharge-free sacral neuromodulation systems (SNM) including Axonics F15 and R20 systems for treating overactive bladder, fecal incontinence and urinary retention. It also offers Bulkamid, a urethral bulking agent for female stress urinary incontinence. The company operates in France, the UK, Australia, Germany and the US. Axonics is headquartered in Irvine, California, the US.

For a complete picture of Axonics, Neuromodulation Devices pricing in the US, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Medical Intelligence Center Market Models are the gold standard of medical device market valuation, company share estimation and market trend forecasting. GlobalData uses a patient-based forecast model or installed base methodology to determine the market size for therapeutic indications and capital equipment expenditures. Estimates are based on a number of sources, including primary research—KOL and industry contact interviews—and secondary research, such as company reports, press releases, published articles, proprietary databases, and general news media.